High-dose firosemide is considered effective in primary renal
sodium retention but is not generally recommended in
congestive heart failure. In order to evaluate efficacy and safety of high-dose
furosemide (greater than 500 mg/day), the authors studied 20 patients (pts) resistant to
therapy (including
furosemide less than 500 mg/day) selected from 161 pts admitted for chronic
heart failure. All refractory pts (15 men and 5 women, mean age sixty +/- 12 years) were in NYHA class IV and showed
hyponatremia (130 +/- 5 mEq/L) and impaired renal function (BUN 31 +/- 14 mg/dL, serum
creatinine 1.3 +/- 0.3 mg/dL and BUN/
creatinine ratio 23 +/- 7). In addition to digitalis,
dopamine,
angiotensin-converting enzyme inhibitors, or
vasodilators, IV high-dose
furosemide (775 +/- 419 mg/day, 500-2000) was given for ten +/- five days under daily clinical and laboratory monitoring. Three pts died of low-output syndrome while 16 pts were upgraded to NYHA class III and 1 pt to class II; a mean
weight reduction of 7.3 +/- 2.9 kg in ten + five days (0.80 +/- 0.4 kg/day) and a mean diuresis increase of 88 +/- 57% occurred. The maximal dose of
furosemide did not correlate with serum
creatinine but did correlate with BUN/
creatinine ratio (r = 0.78, p less than .001). Pts were discharged on with chronic
heart failure, and 43% in the subgroup in NYHA class IV with
hyponatremia. High dose
furosemide was effective for rapid removal of excess water and
salt in "
furosemide-resistant"
congestive heart failure. The relationship between renal impairment and maximal
furosemide doses seems to confirm the role of renal pharmacokinetics in the appearance of
furosemide resistance.